Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese HSK 1 Your complete learning platform for speakers of 21 languages: Arabic, Bengali, Dutch, English, Farsi, French, German, Hindi, Indonesian, Italian, Japanese, Korean, Portuguese, Russian, Spanish, Tagalog, Thai, Turkish, Ukrainian, Urdu, Vietnamese. By Bernd Sebastian Kamps and Andrea Melis

Breast Cancer

Free Subscription Articles published in Histopathology Retrieve available abstracts of 65 articles: HTML format

Single Articles

May 2026
1. PANG JB, Gorringe KL, Tan PH, Fox SB, et al
   Molecular pathology of phyllodes tumours of the breast-much more than MED12.
   Histopathology. 2026;88:1115-1125.
   PubMed     Abstract available
   
   
   
2. INGYIN H, Solomon JP, Li Y, Xu D, et al
   Genetic and immunohistochemical studies identify recurrent ACTB mutations and PTEN alterations in tubular adenomas of the breast.
   Histopathology. 2026;88:1229-1235.
   PubMed     Abstract available
   
   
   
3. KRINGS G, Hashem S, Apushkin MA, Ang-Rabanes TL, et al
   Tall cell carcinoma with reversed polarity of the breast harbouring IDH1 hotspot mutation: morphologic, immunohistochemical and genetic characterization of two cases.
   Histopathology. 2026;88:1212-1220.
   PubMed     Abstract available
   
   
   April 2026
4. SHEPHERD DJ, Craig C, Valencia-Guerrero AL, Chattu S, et al
   Prostein (p501s) is expressed in primary extramammary Paget disease.
   Histopathology. 2026;88:1094-1098.
   PubMed     Abstract available
   
   
   
5. MISRA S, Gudi M, Allison KH, Brogi E, et al
   Mucin-producing breast lesions: a practical approach to diagnosis.
   Histopathology. 2026;88:939-957.
   PubMed     Abstract available
   
   
   
6. ZUO K, Shui R, Xu X, Yu B, et al
   Apocrine encapsulated papillary carcinoma: a comprehensive clinicopathological analysis of 28 cases.
   Histopathology. 2026;88:1075-1083.
   PubMed     Abstract available
   
   
   March 2026
7. 
   Correction to 'A simple digital image analysis system for automated Ki67 assessment in primary breast cancer'.
   Histopathology. 2026 Mar 11. doi: 10.1111/his.70123.
   PubMed    
   
   
   
8. RAKHA EA, Tan PH, Raymond WA
   The spectrum of breast in situ papillary carcinomas with invasion and invasive breast carcinomas with papillary features: an overview of histological subtypes and diagnostic challenges.
   Histopathology. 2026;88:747-768.
   PubMed     Abstract available
   
   
   
9. NAKAMURA H, Kukita Y, Kittaka N, Kusama H, et al
   Apocrine carcinoma of the breast: distinctive metabolic reprogramming and high-frequency PIK3CA mutations revealed by molecular and immunohistochemical analysis.
   Histopathology. 2026;88:790-809.
   PubMed     Abstract available
   
   
   February 2026
10. D'ARRIGO C, Tuzlali S, Barroso-Sousa R, El Saghir NS, et al
    Real-world prevalence of PD-L1 positivity in early-stage/metastatic triple-negative breast cancer: primary results and pathology insights from the global retrospective observational VANESSA study.
    Histopathology. 2026 Feb 22. doi: 10.1111/his.70091.
    PubMed     Abstract available
    
    
    
11. LLEWELLYN A, Brown A, Morel J, Naidoo K, et al
    To VAE or not to VAE: outcomes of radial scars/complex sclerosing lesions and papillary lesions without atypia in the King's College Hospital breast service (2017-2023).
    Histopathology. 2026;88:583-590.
    PubMed     Abstract available
    
    
    January 2026
12. HUANG CY, Wang YJ, Hsieh MS, Lin PY, et al
    Tumour-infiltrating lymphocytes, tertiary lymphoid structures and myxoid stroma predict upstaging of ductal carcinoma in situ in breast biopsies.
    Histopathology. 2026;88:471-487.
    PubMed     Abstract available
    
    
    
13. YE Q, Estrella J, Kalhor N, Liu A, et al
    TRPS1 expression in neuroendocrine neoplasms of breast and other organs.
    Histopathology. 2026;88:524-532.
    PubMed     Abstract available
    
    
    December 2025
14. KAIN ZE, Baez-Navarro X, Linn SC, van Deurzen CHM, et al
    Decision-making in breast pathology reporting: the effect of clinical relevant thresholds.
    Histopathology. 2025;87:951-955.
    PubMed     Abstract available
    
    
    
15. SUN M, Fu L, Ren H, Wang J, et al
    Two similar but distinct types of breast acinar cell carcinoma: evidence from histological, immunohistochemical and molecular features.
    Histopathology. 2025;87:904-914.
    PubMed     Abstract available
    
    
    
16. STA INES FM, Eadara A, Quddus MR, Sung CJ, et al
    Re-appraisal of mucocele-like lesion of the breast with atypia: study of 34 cases with focus on impact of type and extent of atypia on upgrade.
    Histopathology. 2025;87:943-950.
    PubMed     Abstract available
    
    
    September 2025
17. MAKHLOUF S, Almalki N, Sheha A, Atallah NM, et al
    Outcome prediction of oestrogen receptor-positive breast cancer based on a panel of oestrogen receptor-regulated genes.
    Histopathology. 2025 Sep 12. doi: 10.1111/his.15557.
    PubMed     Abstract available
    
    
    August 2025
18. SALISBURY T, Rendi M, Bhalli R, Bean GR, et al
    DCIS-like invasive carcinoma of the breast with tumour-associated microvasculature mimicking myoepithelium: a diagnostic pitfall.
    Histopathology. 2025;87:246-257.
    PubMed     Abstract available
    
    
    
19. HAN R, Hashmi AA, Wen HY, Murray M, et al
    Clinicopathological features of microinvasive lobular carcinoma.
    Histopathology. 2025;87:235-245.
    PubMed     Abstract available
    
    
    
20. TAN PH, Ellis IO, Allison KH, Badve SS, et al
    Malignant phyllodes tumours of the breast: the case for revising WHO's 'full house' diagnostic criteria.
    Histopathology. 2025;87:169-182.
    PubMed     Abstract available
    
    
    July 2025
21. LEE AHS, Rakha EA, Hodi Z, Abbas A, et al
    Retesting of oestrogen receptor, progesterone receptor and HER2 status of invasive carcinoma of the breast after neoadjuvant chemotherapy.
    Histopathology. 2025;87:58-67.
    PubMed     Abstract available
    
    
    June 2025
22. LAOKULRATH N, Nasir NDM, Gudi M, Tan PH, et al
    Diagnostic accuracy and challenges of intraoperative frozen section evaluation for axillary sentinel lymph node biopsy and breast margins.
    Histopathology. 2025;86:1121-1136.
    PubMed     Abstract available
    
    
    
23. AL-REFAI R, Ali A, Roychoudhury S, Bendari A, et al
    Male breast atypical ductal hyperplasia (ADH): clinicopathological insights from a rare cohort.
    Histopathology. 2025;86:1137-1146.
    PubMed     Abstract available
    
    
    May 2025
24. SOKOLOVA A, Joshi V, Chittoory H, Walsh M, et al
    ROS1 immunohistochemistry as a potential predictive biomarker for ROS1-targeted therapy in breast cancer: impact of antibody clone selection.
    Histopathology. 2025 May 13. doi: 10.1111/his.15465.
    PubMed     Abstract available
    
    
    
25. EL SHEIKH S, Mansour MA, Provenzano E, Shaaban A, et al
    Diagnostic interobserver variability of atypia assessment in columnar cell lesions among a group of expert breast pathologists in the United Kingdom and the Republic of Ireland, on behalf of the UK national coordinating committee for breast pathology.
    Histopathology. 2025;86:953-966.
    PubMed     Abstract available
    
    
    
26. HONG R, Wang H, Lin Y, Yin X, et al
    The clinicopathological and molecular features of primary high-grade neuroendocrine tumour in the breast.
    Histopathology. 2025;86:900-915.
    PubMed     Abstract available
    
    
    April 2025
27. BOYRAZ B, Robinson B, Lindeman N, Hoda SA, et al
    Subareolar sclerosing ductal hyperplasia shows PI3K pathway alterations.
    Histopathology. 2025;86:824-827.
    PubMed     Abstract available
    
    
    
28. KHEDR M, Gandhi S, Roy AM, Alharbi M, et al
    Breast biomarkers evolution between primary and distant metastasis: incidence and significance.
    Histopathology. 2025;86:793-804.
    PubMed     Abstract available
    
    
    
29. KATAYAMA A, Makhlouf S, Toss MS, Oyama T, et al
    Nuclear morphological characterisation of lobular carcinoma variants: a morphometric study.
    Histopathology. 2025;86:813-823.
    PubMed     Abstract available
    
    
    
30. KRINGS G, Shamir ER, Lae M, Bean GR, et al
    Serous-like breast carcinomas: immunophenotypic, genetic, and clinicopathologic characterization of a morphologically distinct group of tumours.
    Histopathology. 2025;86:779-792.
    PubMed     Abstract available
    
    
    
31. YANG E, Fineberg S, Mohamed A, Brogi E, et al
    Variability in the diagnosis and reporting of metaplastic breast carcinoma: results of an international survey.
    Histopathology. 2025;86:742-749.
    PubMed     Abstract available
    
    
    March 2025
32. KIM M, Lee M, Lee A, Choi BO, et al
    Correlating p53 immunostaining patterns with somatic TP53 mutation and functional properties of mutant p53 in triple-negative breast cancer.
    Histopathology. 2025 Mar 31. doi: 10.1111/his.15453.
    PubMed     Abstract available
    
    
    
33. CHAN R, Leung H, Li J, Poon I, et al
    Evaluation of breast-specific marker expression in metastatic breast cancers: Correlation with subtype switch.
    Histopathology. 2025;86:536-546.
    PubMed     Abstract available
    
    
    
34. RAKHA EA, Quinn C
    Controversies regarding encapsulated papillary carcinoma of the breast: an approach to evaluation and categorisation.
    Histopathology. 2025;86:497-513.
    PubMed     Abstract available
    
    
    February 2025
35. AI D, Arrey EN, Postlewait LM, Gao Y, et al
    The prevalence and clinical significance of residual occult breast cancer after neoadjuvant chemotherapy: reassessing surgical pathology in cases initially described as pathological complete response.
    Histopathology. 2025 Feb 4. doi: 10.1111/his.15417.
    PubMed     Abstract available
    
    
    
36. YANG E, D'Alfonso TM, Morrow M, Brogi E, et al
    Discordance of human epidermal growth factor receptor 2-low status between breast primary and distant metastases with clinical-pathological correlation.
    Histopathology. 2025;86:441-449.
    PubMed     Abstract available
    
    
    
37. TAHA SR, Boulos F
    E-cadherin staining in the diagnosis of lobular versus ductal neoplasms of the breast: the emperor has no clothes.
    Histopathology. 2025;86:327-340.
    PubMed     Abstract available
    
    
    January 2025
38. ASHI A, Awaji AA, Bond J, Johnson CA, et al
    Threonine and tyrosine kinase (TTK) mRNA and protein expression in breast cancer; prognostic significance in the neoadjuvant setting.
    Histopathology. 2025 Jan 7. doi: 10.1111/his.15399.
    PubMed     Abstract available
    
    
    
39. LEE AHS, Hodi Z, Abbas A, Ellis IO, et al
    HER2-positive grade 1 invasive carcinomas of the breast.
    Histopathology. 2025;86:278-284.
    PubMed     Abstract available
    
    
    December 2024
40. WANG Y, Liu L, Graff SL, Cheng L, et al
    Recent advancements in biomarkers and molecular diagnostics in hormonal receptor-positive breast cancer.
    Histopathology. 2024 Dec 17. doi: 10.1111/his.15395.
    PubMed     Abstract available
    
    
    
41. ONAGI H, Horimoto Y, Okano S, Sasa K, et al
    Clinicopathological characteristics of Japanese patients with breast cancer and MET exon 14 skipping alterations.
    Histopathology. 2024 Dec 4. doi: 10.1111/his.15382.
    PubMed     Abstract available
    
    
    
42. HEMPENIUS MA, Eenkhoorn MA, Hoeg H, Dabbs DJ, et al
    Quantitative comparison of immunohistochemical HER2-low detection in an interlaboratory study.
    Histopathology. 2024;85:920-928.
    PubMed     Abstract available
    
    
    October 2024
43. MATSUMOTO H, Miyata R, Tsuruta Y, Nakada N, et al
    Ki-67 evaluation using deep-learning model-assisted digital image analysis in breast cancer.
    Histopathology. 2024 Oct 31. doi: 10.1111/his.15356.
    PubMed     Abstract available
    
    
    
44. WANG Y, Liu L, Graff SL, Cheng L, et al
    Locoregional event or dyssynchronous distant metastasis: clinicopathological and molecular analysis of contralateral axillary lymph node metastasis in breast cancer patients.
    Histopathology. 2024 Oct 22. doi: 10.1111/his.15345.
    PubMed     Abstract available
    
    
    September 2024
45. WONG CJW, Md Nasir ND, Koh VCY, Campbell F, et al
    Mapping the cited evidence of ductal carcinoma in situ from the 5th edition of the World Health Organisation classification of tumours of the breast.
    Histopathology. 2024;85:510-520.
    PubMed     Abstract available
    
    
    
46. BATRA H, Bose PSC, Ding Y, Dai A, et al
    MYB expression by immunohistochemistry is highly specific and sensitive for detection of solid variant of adenoid cystic carcinoma of the breast among all triple-negative breast cancers.
    Histopathology. 2024;85:503-509.
    PubMed     Abstract available
    
    
    
47. TURASHVILI G
    Nonneoplastic and neoplastic sclerosing lesions of the breast.
    Histopathology. 2024;85:383-396.
    PubMed     Abstract available
    
    
    
48. GRABENSTETTER A, Brennan SB, Jochelson MS, Brogi E, et al
    Radial sclerosing lesions found on core needle biopsy: excision can be safely avoided.
    Histopathology. 2024;85:397-404.
    PubMed     Abstract available
    
    
    
49. ELLIS I, Webster F, Allison KH, Dang C, et al
    Dataset for reporting of the invasive carcinoma of the breast: recommendations from the International Collaboration on Cancer Reporting (ICCR).
    Histopathology. 2024;85:418-436.
    PubMed     Abstract available
    
    
    August 2024
50. ZWAGER MC, Yu S, Buikema HJ, de Bock GH, et al
    Advancing Ki67 hotspot detection in breast cancer: a comparative analysis of automated digital image analysis algorithms.
    Histopathology. 2024 Aug 5. doi: 10.1111/his.15294.
    PubMed     Abstract available
    
    
    July 2024
51. BANNIER PA, Broeckx G, Herpin L, Dubois R, et al
    Development of a deep-learning model tailored for HER2 detection in breast cancer to aid pathologists in interpreting HER2-low cases.
    Histopathology. 2024 Jul 14. doi: 10.1111/his.15274.
    PubMed     Abstract available
    
    
    
52. TOZBIKIAN G, Bui MM, Hicks DG, Jaffer S, et al
    Best practices for achieving consensus in HER2-low expression in breast cancer: current perspectives from practising pathologists.
    Histopathology. 2024 Jul 8. doi: 10.1111/his.15275.
    PubMed     Abstract available
    
    
    
53. ZHANG H, Finkelman BS, Ettel MG, Velez MJ, et al
    HER2 evaluation for clinical decision making in human solid tumours: pearls and pitfalls.
    Histopathology. 2024;85:3-19.
    PubMed     Abstract available
    
    
    June 2024
54. LASHEN AG, Toss M, Miligy I, Rewcastle E, et al
    Nottingham prognostic x (NPx): a risk stratification tool in ER-positive HER2-negative breast cancer: a validation study.
    Histopathology. 2024 Jun 13. doi: 10.1111/his.15234.
    PubMed     Abstract available
    
    
    
55. MILIGY IM, Awasthi R, Mir Y, Khurana A, et al
    Morphological and molecular changes of oestrogen receptor-positive breast cancer following bridging endocrine therapy: a United Kingdom multicentre study.
    Histopathology. 2024 Jun 7. doi: 10.1111/his.15238.
    PubMed     Abstract available
    
    
    
56. LAOKULRATH N, Gudi M, Salahuddin SA, Chong APY, et al
    Human epidermal growth factor receptor 2 (HER2) status in breast cancer: practice points and challenges.
    Histopathology. 2024 Jun 6. doi: 10.1111/his.15213.
    PubMed     Abstract available
    
    
    
57. BOSSUYT V, Provenzano E, Symmans WF, Webster F, et al
    A dedicated structured data set for reporting of invasive carcinoma of the breast in the setting of neoadjuvant therapy: recommendations from the International Collaboration on Cancer Reporting (ICCR).
    Histopathology. 2024;84:1111-1129.
    PubMed     Abstract available
    
    
    May 2024
58. LI J, Dong P, Wang X, Zhang J, et al
    Artificial intelligence enhances whole-slide interpretation of PD-L1 CPS in triple-negative breast cancer: A multi-institutional ring study.
    Histopathology. 2024 May 15. doi: 10.1111/his.15205.
    PubMed     Abstract available
    
    
    
59. HUANG CY, Chang RF, Lin CY, Hsieh MS, et al
    Deep-learning model to improve histological grading and predict upstaging of atypical ductal hyperplasia / ductal carcinoma in situ on breast biopsy.
    Histopathology. 2024;84:983-1002.
    PubMed     Abstract available
    
    
    April 2024
60. BADR NM, Zaakouk M, Zhang Q, Kearns D, et al
    Concordance between ER, PR, Ki67, and HER2-low expression in breast cancer by MammaTyper RT-qPCR and immunohistochemistry: implications for the practising pathologist.
    Histopathology. 2024 Apr 23. doi: 10.1111/his.15193.
    PubMed     Abstract available
    
    
    
61. LI JJX, Ni SYB, Tsang JYS, Chan WY, et al
    Neutrophil-lymphocyte ratio reflects tumour-infiltrating lymphocytes and tumour-associated macrophages and independently predicts poor outcome in breast cancers with neoadjuvant chemotherapy.
    Histopathology. 2024;84:810-821.
    PubMed     Abstract available
    
    
    
62. ALKHAYYAT R, Abbas A, Quinn CM, Rakha EA, et al
    Tumour 63 protein (p63) in breast pathology: biology, immunohistochemistry, diagnostic applications, and pitfalls.
    Histopathology. 2024;84:723-741.
    PubMed     Abstract available
    
    
    
63. AZAM AS, Tsang YW, Thirlwall J, Kimani PK, et al
    Digital pathology for reporting histopathology samples, including cancer screening samples - definitive evidence from a multisite study.
    Histopathology. 2024;84:847-862.
    PubMed     Abstract available
    
    
    March 2024
64. LY A, Garcia V, Blenman KRM, Ehinger A, et al
    Training pathologists to assess stromal tumour-infiltrating lymphocytes in breast cancer synergises efforts in clinical care and scientific research.
    Histopathology. 2024 Mar 3. doi: 10.1111/his.15140.
    PubMed     Abstract available
    
    
    November 2023
65. CSERNI G, Kalman E, Udvarhelyi N, Papp E, et al
    Evaluation of the routine use of E-cadherin immunohistochemistry in the typing of breast carcinomas: results of a randomized diagnostic study.
    Histopathology. 2023;83:810-821.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum